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Evolutionary adaptation of Pseudomonas aeruginosa to the cystic fibrosis lung is limited by genetic variation,
which depends on rates of horizontal gene transfer and mutation supply. Because each may increase following
secondary infection or mutator emergence, we sought to ascertain the incidence of secondary infection and
genetic variability in populations containing or lacking mutators. Forty-nine strains collected over 3 years from
16 patients were phenotyped for antibiotic resistance and mutator status and were genotyped by repetitive-
sequence PCR (rep-PCR), pulsed-field gel electrophoresis (PFGE), and multilocus sequence typing (MLST).
Though phenotypic and genetic polymorphisms were widespread and clustered more strongly within than
between longitudinal series, their distribution revealed instances of secondary infection. Sequence data,
however, indicated that interlineage recombination predated initial strain isolation. Mutator series were more
likely to be multiply antibiotic resistant, but not necessarily more variable in their nucleotide sequences, than
nonmutators. One mutator and one nonmutator series were sequenced at mismatch repair loci and analyzed
for gene content using DNA microarrays. Both were wild type with respect to mutL, but mutators carried an
8-bp mutS deletion causing a frameshift mutation. Both series lacked 126 genes encoding pilins, siderophores,
and virulence factors whose inactivation has been linked to adaptation during chronic infection. Mutators
exhibited loss of severalfold more genes having functions related to mobile elements, motility, and attachment.
A 105-kb, 86-gene deletion was observed in one nonmutator that resulted in loss of virulence factors related to
pyoverdine synthesis and elements of the multidrug efflux regulon. Diminished DNA repair activity may
facilitate but not be absolutely required for rapid evolutionary change.
Pseudomonas aeruginosa is a primary agent of chronic en-
dobronchial infection in the cystic fibrosis (CF) lung after early
childhood. CF patients commonly succumb to clonal descen-
dants of P. aeruginosa strains acquired early in life (10, 60, 91).
Because chronic infections can last for years, P. aeruginosa
populations undergo thousands of generations challenged by
antibiotic treatment, iron depletion (95), hydrophobicity (73),
immune system surveillance, microbial competitors, and the
changing topography of the CF lung (36, 56, 77). P. aeruginosa
adapts physiologically to these challenges via complex regula-
tory networks that coordinate expression of its large genome.
Approximately one in 10 genes in the sequenced PAO1 lab
strain are regulatory, many of which influence transport, ca-
tabolism, and efflux of organic compounds, including antibiot-
ics (81). The adaptability of P. aeruginosa is also evident in the
high ratio of paralogous gene groups represented in its genome
(76), a feature that may enable the species to explore adaptive
space by neofunctionalization.
P. aeruginosa exhibits remarkable genome plasticity. In nat-
urally occurring isolates, the genome size ranges between 5.2
Mbp and 7 Mbp (87) and consists of a core genome, conserved
both in organization and orientation, and various accessory
elements prone to recombination (92). These elements range
in size from 1 to 200 kbp and account for 15 to 30% of the
genomic diversity observed among clonal isolates (46, 47).
Such observations have given rise to the distributed-genome
hypothesis (DGH), which posits that each P. aeruginosa clone
contains a unique collection of genes drawn from a hypothet-
ical “pangenome” that encompasses all genes in the global P.
aeruginosa population (76). Because these genes are unequally
distributed among clones, P. aeruginosa exhibits phenotypic
variability with respect to virulence, metabolic repertoire, and
patterns of gene regulation (92). Studies of clonal diversity
indicate that within any lineage the P. aeruginosa genome is
malleable, frequently given to local changes that result in sin-
gle-base substitutions, insertions, or deletions (indels) and re-
gional changes that result in deletions, duplications, and inver-
sions (69, 70, 72). In the CF lung such mutations appear more
likely to be propagated by vertical gene transfer (VGT) than by
horizontal gene transfer (HGT) (80, 93), although superinfec-
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tion (57) and between-patient cross-infection (41) have both
been reported.
When ecological or genetic factors limit HGT between bac-
terial lineages, the rate of adaptive evolutionary change de-
pends on the rate of mutation supply (5). If the effective pop-
ulation size is low and selection pressure is high, strains with
elevated mutation rates may be competitively advantaged (5),
especially if the population is not well adapted and/or if adap-
tation requires sequential selection of multiple beneficial mu-
tations (18). “Mutator” phenotypes may manifest transiently
following a stress-induced increase in the expression of recom-
bination enzymes and/or error-prone polymerases (4, 12).
Conversely, they may manifest constitutively and heritably as a
result of mutations that cause unregulated expression of these
or other enzymes involved in DNA proofreading and repair
(32, 61, 64). Because heritable mutators commonly arise from
defects in methyl-directed mismatch repair (MMR) (e.g., mutS
and mutL), they are more susceptible not only to single-base-
pair substitutions but also to homologous recombination (ref-
erences 18 and 63and references therein), making them sus-
ceptible to genome rearrangement and HGT (68).
Oliver et al. (61) reported a high prevalence of heritable P.
aeruginosa mutators in chronic CF infections (approximately
37%) but not in acute P. aeruginosa pulmonary infections of
non-CF patients. Because mutators exhibit mutation frequen-
cies that exceed wild-type frequencies by an order(s) of mag-
nitude, more deleterious than beneficial mutations are likely to
accumulate in their descendant lineages. As a result, one
would expect mutators to come under purifying selection soon
after they arise (32). The high incidence of mutators in CF
patients with chronic respiratory infection (CRI) suggests that
these strains not only persist by “hitchhiking” with beneficial
mutations but also are peculiarly adept at doing so in the CF
lung owing to environmental complexity (62) and/or to an
increased incidence of compensatory mutations that offset fit-
ness costs of drug resistance (65). Interestingly, laboratory-
cultured P. aeruginosa biofilm microcolonies become highly
enriched in mutators (13, 60), and drug-resistant P. aeruginosa
mutator populations resist invasion by drug-sensitive nonmu-
tators, even in the absence of selection (65). Presently, our
understanding of the relative contribution of mutators to adap-
tive genetic variation in CF CRI consists chiefly of a limited
number of studies that link them statistically to an increased
incidence of multiple antibiotic resistance (MAR) (21, 30),
decreased lung function (21, 89), and the emergence of CRI-
specific adaptive genotypes (58).
To increase our understanding of the role that mutators may
play in producing adaptive variation, we investigated the phe-
notypic and genotypic diversity in 49 clinical P. aeruginosa
isolates from 16 CF patients treated over a 3-year period at
Necker Children’s Hospital in Paris, France. Each isolate was
characterized phenotypically with respect to mucoidy, sensitiv-
ity to multiple classes of antibiotics, and frequency with which
it spontaneously produced rifampin-resistant mutants and then
was characterized genetically via multilocus sequence typing
(MLST) and pulsed-field gel electrophoresis (PFGE)/repeti-
tive-sequence PCR (rep-PCR) genome fingerprinting (15, 27,
84). Two age-matched series, similar in duration but different
in mutator incidence, were sequenced at the mutL and mutS
loci and subjected to detailed genomic analysis using Af-
fymetrix PAO1 microarrays (93). Our overall goals were to test
the hypotheses that P. aeruginosa evolved clonally within indi-
vidual patients in the absence of secondary infection and re-
combination and that genetic diversity, estimated as either
nucleotide polymorphism or structural variation, was greater in
populations from which mutators were isolated than in popu-
lations from which they were not.
MATERIALS AND METHODS
Strain collection. P. aeruginosa isolates were obtained from the Laboratory of
Microbiology of the Hôpital Necker-Enfants Malades, Paris, France. A total of
49 strains from 16 patients were examined; 47 constituted 15 longitudinal series,
as they were isolated from the sputa of patients seen on multiple occasions in the
clinic. The longest interval between initial and final samples was 25 months, and
the shortest was 2 months. Patients ranged in age from 6 months to 20 years
(mean, 11.9 years; standard deviation [SD], 4.5 years). To protect confidentiality,
letters were substituted for patient names. Longitudinal series obtained from
patients I and M were age matched as a surrogate for infection duration (the
patients were 13.5 and 14.9 years old, respectively, at the start of collection); as
such, both series likely represent intermediate or late stages of adaptation to
chronic infection.
Clinical isolates were obtained as previously described (21), colony purified
from selective Pseudomonas isolation agar (PIA), and then frozen as 80°C
glycerol stocks. Strains PAO1 and PA14 were provided by Samuel Miller, Uni-
versity of Washington.
Phenotypic characterization. Archived samples were tested for susceptibility
to amikacin (30 g), tobramycin (10 g), ciprofloxacin (5 g), and ticarcillin (75
g) by disc diffusion assay and scored for resistance, sensitivity, or intermediate
resistance using guidelines established by CAFSM (Comité de l’Antibiogramme
de la Société Française de Microbiologie). Strains found to have complete or
intermediate resistance to three or more classes of drugs were defined as MAR
(Table 1). Mucoidy was assayed by plating isolates on PIA agar and then scoring
colony morphology after aerobic growth at 37°C for 15 h followed by anaerobic
growth at 37°C for 12 h, as previously described (9).
Mutator screening. Mutation frequency was estimated as described in refer-
ence 21 by plating cells on Mueller-Hinton (MH) agar supplemented with 300 g
ml1 of rifampin (Rif) (ICN, Fair Lawn, NJ). Briefly, glycerol stocks were
streaked on PIA agar and grown overnight at 32°C. For each strain, three freshly
grown colonies were used to inoculate 4-ml cultures of MH broth. Following
overnight growth at 32°C, 100 l of 106, 107, and 108 dilutions were plated
in triplicate on MH agar, while 100 l of 100, 101, and 102 dilutions were
plated on MH-Rif. Plates were incubated at 32°C for 24 h and 48 h, respectively,
and mutation frequencies estimated by dividing the total number of spontaneous
Rifr mutants estimated from colonies on MH-Rif agar by the total number of all
bacteria estimated from colony number on nonselective agar. “Mutators” were
defined as clones where Rifr mutants appeared at a frequency 1 order of mag-
nitude greater than the population median value of 2.5  108.
gDNA extractions. Genomic DNA (gDNA) extractions were performed using
a cetyltrimethylammonium bromide (CTAB) method of phenol-chloroform ex-
traction (6) after overnight culture in Pseudomonas F broth, adjusting the num-
ber of extractions as necessary for mucoid strains. Genomic DNA was visualized,
quantified, and verified for purity using gel electrophoresis and spectrophotom-
etry.
rep-PCR. Enterobacterial repetitive intergenic consensus sequence (ERIC)
and BOXA1 (88) primers were independently used to produce repetitive-se-
quence PCR (rep-PCR) fingerprints. rep-PCR amplicons were electrophoresed
at 4°C and 70V for 14.5 h in 250-ml 1.5% (wt/vol) agarose gels made up 1
Tris-acetate-EDTA (TAE) (40 mM Tris-acetate, 1 mM EDTA, pH 8.0), with
continuous recirculation of 1 TAE buffer.
PFGE. (i) Plug preparation. Pulsed-field gel electrophoresis (PFGE) plugs
(100 l) were prepared according to methods outlined in the CHEF-DR II
instruction manual (no. 170-3612 through 170-3729) with modifications de-
scribed below. P. aeruginosa cultures were grown overnight in 4 ml Luria-Bertani
(LB) medium and diluted to an A600 of 0.8 to 1.0 using sterile LB, after which
1.0 ml of diluted culture was transferred to a 1.5-ml Eppendorf tube containing
180 g chloramphenicol. A 100-l aliquot of this culture was centrifuged for 3
min in a Sorvall MC12V centrifuge at 9,660 g and then resuspended in 50 l of
cell suspension buffer containing 5 mM EDTA.
(ii) Restriction digestion and electrophoresis. To produce two PFGE finger-
prints, duplicate plugs were prepared for each clone. Chromosomal DNA was
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restriction digested using either SpeI or DraI (New England BioLabs, Ipswich,
MA) by first equilibrating plugs for 1 h in 0.5 ml of NEBuffer 2 or NEBuffer 4 and
then digesting plugs for 4 h with 20 U restriction enzyme in 0.3 ml of the
appropriate 1 buffer with 0.1 mg ml1 bovine serum albumin (BSA). Following
digestion, plugs were washed for 30 min in 1 wash buffer. Contour-clamped
homogeneous electric field (CHEF) plugs were loaded onto 160-ml 1% (wt/vol)
agarose gels and electrophoresed in 2 liters of 0.5 Tris-borate-EDTA (TBE)
buffer, pH 8.3, at 12°C in a Bio-Rad CHEF-DR II apparatus (Bio-Rad, Hercules,
CA). Each cycle was run at 6 V cm1 at an angle of 120°, with pulse times of from
1 to 60 s for 31 h.
Image analysis. rep-PCR and PFGE gel images were downloaded into Bionu-
merics v4.50. (Applied Maths, Sint-Martens-Latem, Belgium) and standardized
using 1-kb ladders and Lambda ladder PFG markers (Promega, Madison, WI),
and dendrograms were produced using Jaccard correlations, which account for
band number and spacing. Images were analyzed as composite data sets so that
each band could be assigned to a group specifying its gel position. Following
band assignment, a Bootstrap analysis of 1,000 cycles was performed to assign
confidence values to the dendrograms. Bootstrap values greater than or equal to
70% are reported (34).
MLST. PCR amplification from genomic DNA and subsequent sequencing
were performed using primers specific for acsA, aroE, guaA, mutL, nuoD, ppsA,
and trpE (http://pubmlst.org/paeruginosa/info/primers.shtml) designed by Cur-
ran et al. (14). Amplification reaction mixtures were prepared in 50-l volumes
consisting of 40 ng of genomic DNA, 1 PCR buffer minus MgCl2 (Invitrogen,
Carlsbad, CA), 1.5 mM MgCl2 (Invitrogen), 0.2 mM exACTGene PCR deoxy-
nucleoside triphosphate (dNTP) mix (Fisher BioReagents, Pittsburgh, PA), 0.5
M each primer (Sigma-Genosys, St. Louis, MO), and 1.25 U Taq DNA poly-
merase (Invitrogen) using standard P. aeruginosa multilocus sequence typing
TABLE 1. Phenotypic variation in the Necker collection
Patient Strain Isolation date(mo/day/yr)
Phenotype Frequency of
spontaneous
Rifr mutantsa
Resistanceb
Mucoid Mutator MAR Ami Cip Tob Tic
A A1 3/13/2002    3.60E08 R S S R
A2 1/15/2003    4.15E08 S S S S
B B1 2/25/2002    1.60E08 I S S S
B2a 2/10/2003    1.00E08 R S S S
B2b    5.10E09 R I S S
C C1 3/5/2002    5.00E09 I S R R
C2a 8/22/2002    2.00E09 R S R I
C2b    1.00E08 I S R R
D D1 10/15/2002    5.60E08 I S S R
D2 9/5/2003    1.25E07 R S I S
E E1 1/13/2002    1.93E09 R S I S
E2 11/8/2002    1.46E05 R S S S
F F1 12/10/2001    2.00E09 R S R R
F2 1/29/2003    5.85E09 R S S S
G G1 3/6/2002    3.85E08 S S S S
G2 2/13/2003    7.70E09 S S S S
H H1 1/25/2002    6.10E06 R I I R
H2 5/30/2002    1.27E05 I S S R
I I1 2/16/2002    1.30E06 R I S R
I2 9/12/2002    1.29E06 R R S R
I3a 9/25/2002    1.25E07 R S S S
I3b    1.95E07 R R I R
I4 3/14/2003    3.90E08 R I S R
J J1 3/6/2002    7.26E07 S I S S
J2a 5/31/2002    1.43E07 S S S S
J2b    4.00E07 R S S S
K K1 3/28/2002    8.75E09 R S S S
K2a 6/18/2002    5.42E08 R S I S
K2b    1.80E08 R S R S
K3a 9/25/2002    1.27E08 R S R S
K3b    5.50E08 R I R R
K4a 9/26/2002    1.60E08 R S S S
K4b    1.50E08 R S I I
K5a 7/1/2003    7.51E08 R S R S
K5b    8.00E08 R S I S
L L1 8/22/2001    0.00E00 R S I S
L2 9/18/2003    2.50E09 R I I S
M M1 10/12/2001    4.88E09 S S S S
M2 8/16/2002    5.55E09 R S R S
M3a 12/19/2002    9.50E09 S S S S
M3b    3.00E09 R S S S
N N1a 6/13/2003    2.88E08 I S S R
N1b    4.00E07 I S S R
O O1 2/26/2002    2.60E09 I S S S
O2 4/28/2003    9.00E09 S I S S
P P1 7/23/2001    6.50E06 I S S S
P2a 10/29/2001    7.60E06 S R S S
P2b    3.54E07 S S S S
P2c    6.00E06 R I I R
a Ami, amikacin; Cip, ciprofloxacin; Tob, tobramycin; Tic, ticarcillin; R, resistant; S, susceptible; I, intermediate.
b Hypermutator strains having a Rifr frequency of 2.5  107 are shaded.
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(MLST) thermal profiles (14). Amplification products were purified with the
QIAquick PCR purification kit (Qiagen Sciences, Valencia, CA) or QIAquick
gel extraction kit (Qiagen) for samples exhibiting nonspecific amplification. In-
ternal fragments of 800- to 1,000-bp amplicons were sequenced on an ABI
3130 Genetic Analyzer. MLST allele assignments were obtained by BLAST
similarity searches against the P. aeruginosa pubMLST database (http://pubmlst
.org/paeruginosa/).
Population genetic analyses by multilocus sequence analysis (MLSA). Se-
quences were aligned using ClustalW with default algorithm parameters (85).
For each MLST locus, DnaSP was used to determine the number of single-
nucleotide polymorphisms (SNPs) and distinct alleles in the sample (72), esti-
mates of the amount of genetic variation, and the minimum number of recom-
bination events (40). Minimum spanning trees (50) were inferred for each locus
from the matrix of pairwise nucleotide differences in Arlequin v2.0 (Genetics and
Biometry, University of Geneva) (75). Subsequently, genealogical networks were
manually derived from these trees such that the sum of the branch lengths
separating two alleles corresponded exactly to the number of nucleotide differ-
ences between them. Genetic differentiation within and between patient series
was estimated by analyses of molecular variance (AMOVA) models imple-
mented in Arlequin using default settings.
mutL and mutS sequencing. Primers were designed using FastPCR 6.0 (C.B.)
and Primer3 (K.C.) and conserved sequences of mutL and mutS from PAO1,
UCBPP-PA14, and LESB58, screened for predicted nonspecific amplification
based on available whole-genome sequences (see Table S1 in the supplemental
material), and then synthesized by Integrated DNA Technologies (Coralville,
IA). PCRs were optimized for MgCl2 concentration and thermal profile, and
betaine added to improve performance. PCR products were purified by Qiagen
gel extraction following visualization and band excision and then Sanger se-
quenced at either the University of Washington or the University of Montana
sequencing facilities. Consensus sequences for each strain were determined using
DNA Baser 2.80.0 with manual editing based on trace quality scores. Alignments
for mutS and mutL were constructed using ClustalW v2.0.12-Win. SNPs, non-
synonymous and synonymous nucleotide diversity (), and DNA polymorphisms
were identified using DnaSP v5. Minimum spanning networks under AMOVA
were determined using Arlequin v3.11 and drawn in Network v4.5.1.6.
a-CGH. Genome content was evaluated for the I and M series (series con-
taining mutators and nonmutators, respectively) by hybridizing genomic DNA to
Affymetrix GeneChip arrays. Array-based comparative genome hybridization
(a-CGH) data were validated by Pathogen Functional Genomics Resource Cen-
ter (PFGRC) arrays (http://pfgrc.jcvi.org/). For Affymetrix a-CGH, 10 mg P.
aeruginosa genomic DNA (gDNA) was fragmented using DNase I for 5 to 10 min
at 37°C, yielding 50- to 200-bp fragments. DNase I was inactivated at 99°C for
15 min. Fragmentation was analyzed using the Agilent Bioanalyzer. Fragmented
gDNA was labeled using terminal deoxynucleotidyl transferase and Affymetrix
GeneChip labeling reagent as specified by the manufacturer. Three milligrams of
fragmented, labeled gDNA was loaded onto Affymetrix PAO1 GeneChips and
incubated at 50°C for 16 h while shaking at 60 rpm. Microarrays were processed
using a GeneChip450 fluidics station and scanned using a GeneChip 7G scanner,
and data were analyzed using GCOS v1.4 and GeneSpring v7.3.a. PFGRC array
experiments were performed according to protocols established by the Pathogen
Functional Genomics Resource Center (http://pfgrc.jcvi.org/index.php
/microarray/protocols.html). The dUTP/dTTP ratio was adjusted to 2:1 to ac-
commodate the high P. aeruginosa G-C content (63%).
Statistical analyses of microarray data. To determine a reliable cutoff value
for calling genes present or absent, pairwise Pearson correlations were computed
for Affymetrix and PFGRC microarray data between corresponding strains hav-
ing nonzero values below a specified cutoff. The maximum average pairwise
correlation occurred at 1.27, with an average correlation value of 0.73. To
establish a confidence interval for this correlation, bootstrapping was performed
at the maximum point for 10,000 repetitions to obtain an estimated standard
deviation of 0.035. The range of cutoff values between 1.60 and 0.96 pro-
duced average correlation values within 2% of the maximum correlation of 0.73.
The lower end of this interval, 1.60, was chosen to minimize the chance of false
positives (see Fig. S2 in the supplemental material).
Nucleotide sequence accession numbers. The sequences reported in this paper
have been deposited in the GenBank database under accession numbers
HQ605971 to HQ605981 (mutL) and HQ632813 to HQ632822 (mutS). MLST
profiles have been submitted to the P. aeruginosa MLST database as isolates 696
to 736 and 755 to 762, sequence types 1007 to 1013 and 1066 to 1069, and novel
trpE alleles trpE136 and trpE137. The CHP and CEL files generated from Af-
fymetrix analyses, as well as normalized and log2 values, have been deposited in
GEO (accession number GSE25481) and can be accessed at http://www.ncbi.nlm
.nih.gov/geo/query/acc.cgi?tokenpfwntyiioqooqfq&accGSE25481.
RESULTS
The Necker P. aeruginosa collection exhibits widespread
phenotypic polymorphism within and among patient series.
We investigated 49 clones isolated from 16 patients whose age
at first P. aeruginosa isolation ranged from 0.6 to 16.3 years
(mean, 12.2 years; SD, 4.4 years). Forty-seven of these isolates
constituted 15 longitudinal series that ranged in duration of
collection from 2 to 25 months (mean, 10.7 months; SD, 5.8
months) (Table 1). Thirty-four isolates were nonmucoid, 15
were mucoid, and 7 were multiply antibiotic resistant (MAR).
The frequency with which Necker strains produced spontane-
ous rifampin-resistant mutants ranged from 1.29  105 to
	1.9  109. Twelve clones exhibiting a Rifr frequency 1 order
of magnitude greater than the population median (2.5  108)
were designated mutators. Mutators were isolated from six
patient series: E (10 months in duration), H (4 months), I (13
months), J (2.5 months), N (0 months), and P (3 months). By
Fisher’s two-tailed exact test we found no significant relation-
ship between mutator status and mucoid status (P  0.73);
however, we did find a significant relationship between muta-
tor and MAR status (P 	 0.05). This finding is consistent with
previous reports that mutators are more likely to be MAR than
nonmutators at the Necker Hospital (21) and elsewhere (54).
Some degree of phenotypic polymorphism was evident in
bacteria from all patients. In 8 of 16 patients, two or more
strains isolated at the same time point differed with respect to
either mucoidy (B, J, and K), antibiotic resistance profile (all
[B, C, I, J, K, M, N, and P]), or mutator status (I, J, and N)
(Table 1). As these phenotypes are vertically transmitted and,
with the exception of mucoidy, stably maintained in the labo-
ratory, we conclude they must have some heritable component.
This finding, especially viewed in the light of the limited num-
ber of samples analyzed, supports the view that the CF lung
contains genetically diverse P. aeruginosa populations, regard-
less of whether that diversity arises solely from mutation or
from the combined forces of spontaneous mutation, horizontal
gene transfer, and secondary infection.
Genome fingerprinting shows that clinical P. aeruginosa
populations are founded by unique strains, evolve clonally,
and undergo within-patient differentiation. rep-PCR and
PFGE are widely used to generate P. aeruginosa genome fin-
gerprints that illuminate clone identity and population struc-
ture (15). The methods are mutually validating, as one is based
on distribution of repetitive-sequence primer sites whereas the
other is based on the distribution of restriction endonuclease
recognition sites. To control for between-experiment variation,
we performed rep-PCR amplifications on the entire collection
simultaneously, using the same master mix. To control for
variation in PFGE banding patterns, we ran the entire collec-
tion on the same gel with multiple lanes of the products from
PAO1. rep-PCR and PFGE data were clustered using Bionu-
merics image analysis software.
Genomic similarities within each lineagevaried, ranging
from 52% to 98% for BOXA1, 78% to 100% for SpeI, 40% to
91% using ERIC, and 71% to 100% for DraI (Fig. 1; see Fig.
S1 in the supplemental material). rep-PCR and PFGE data
provided no evidence that certain fingerprints are more likely
to be seen among initial isolates. Likewise, in no instance did
we observe independent lineages to converge on particular
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FIG. 1. Genomic fingerprinting. (A) rep-PCR using BOXA1 primers; (B) SpeI PFGE of SpeI-digested genomic DNA. Percent similarity is indicated on the
y axis. *, mutator. Numbers at branch points indicate bootstrap values; only values of 70 are reported, as they provide 95% confidence in tree topology (34).
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fingerprints. These observations are consistent with previous
reports that chronic P. aeruginosa infections arise from found-
ers drawn from a genetically diverse environmental reservoir
(71, 93) and that lineages evolve more or less independently
within individual patients (82). Regardless of methodology,
dendrograms show that isolates within patient series are much
more similar to one another than they are to isolates from
other patients. For example, the average within-patient simi-
larity in SpeI PFGE dendrograms is 71.3%, whereas the
among-patient similarity is only 34.2%. This overall trend
holds whether fingerprints are complex (Fig. 1) or simple (see
Fig. S1 in the supplemental material). The inference that with-
in-patient similarity is greater than among-patient similarity is
further supported by bootstrap estimates based on total band
number and total number of distinguishing bands per group
per experimental treatment. High bootstrap values have been
shown to be a conservative estimate of confidence (34), with a
value of 70 corresponding to 95% confidence.
In certain instances, phenotypic differentiation was also
manifest in different genome fingerprints. For example, J2a
and J2b, which differed with respect to all three phenotypes
assayed (Table 1), displayed distinct PFGE genotypes (Fig. 1B;
see Fig. S1B in the supplemental material). In contrast, in the
K series, where phenotypic polymorphism was evident at four
of five time points (Table 1), we observed identical ERIC and
DraI fingerprints (see Fig. S1 in the supplemental material)
but well-differentiated BOXA1 and SpeI patterns (Fig. 1). In
the only instance where a pairwise comparison between a non-
mutator-containing series (M) and a mutator-containing series
(I) of similar duration was possible, we found little correlation
between the presence of mutators and within-lineage genetic
differentiation resolvable by rep-PCR or PFGE. Interestingly,
in the I series we noted that genome fingerprints of hypermu-
tator I2 (Rifr  1.29E06) strongly resembled those of sub-
sequent weak mutator I3a (Rifr  1.25E07) (e.g., similar-
ity  70% and bootstrap  99% [Fig. 1A] and similarity 
95% and bootstrap  89 [Fig. 1B]). This intriguing observation
suggests that a pattern established by or carried within a mu-
tator lineage can appear in a descendant clone having a lower
mutation rate, an interpretation supported by our MLST data
and by mutS sequence data for this series, as discussed below.
MLSA confirms clonal population structure but also pro-
vides evidence for secondary infection in some patients. For
each strain, we sequenced seven loci for multilocus sequence
analysis (MLSA). Necker collection isolates were genetically
diverse, with a total of 151 single-nucleotide polymorphisms
(SNPs) contributing to between 6 and 12 alleles at each locus
(Table 2). With two exceptions, the trpE136 and trpE137 alleles
observed in patients H and I, MLST alleles in the Necker
collection had been previously reported in the pubMLST da-
tabase (http://pubmlst.org/paeruginosa/) (Table 3). Strain al-
lele combinations resulted in 19 distinct sequence types (STs),
11 of which were novel (Table 3). We estimated the amount of
genetic differentiation between strains from different series
with the statistic FST (90), which takes on values of between 0
and 1, with higher values indicating increasing differentiation
between groups. Though some STs were isolated from multiple
series (D and F, L and O, and E and N), we generally observed
extreme genetic differences in strains between patient series
for all loci (Table 2), with FST values ranging between 0.78 and
0.97. In many patients (A, C, D, E, G, K, L, M, and N), the
within-patient STs were identical at different sampling times.
Therefore, MLST data are consistent with rep-PCR and PFGE
data indicating that patients acquire strains from a genetically
diverse environmental reservoir and that once established, bac-
teria evolve clonally.
The FST values suggest that the probability of strain migra-
tion between patients is low. However, MLSA reveals instances
of secondary infection, manifest as multiple genotypes infect-
ing the same individual and one of the genotypes infecting
multiple individuals. Three clones (D1, D2, and F2) from two
patients exhibit identical STs, sharing sequence identity over
5,678 nucleotides (nt) distributed across seven genes (shaded
areas in Table 3). Likewise, both strains from patient L (L1 and
L2) and one strain from patient O (O1) exhibit identical STs
but for a different set of alleles than those infecting patients D
and F. CLONDIAG (Clondiag Chip Technologies, Germany)
biochip analysis of 13 SNPs in conserved genomic regions,
including oriC, citS, ampC, oprI, fliC, oprL, and alkB2 (49), also
supports the inference of co-/cross-infection by these strains
(data not shown). Significantly, all patients in this study over-
lapped in their treatment schedules (see Fig. S5 in the supple-
mental material), and patients D, F, and L were all homozy-
gous for the F508del cystic fibrosis transmembrane
conductance regulator (CFTR) allele that appears to predis-
pose patients to invasion by transmissible P. aeruginosa (45).
Mutator series appear to be no more variable in their MLST
haplotypes than nonmutator series. Whether populations with
mutators are more genetically variable than those without is a
question that has far-reaching implications for understanding
P. aeruginosa evolutionary dynamics in the CF lung. As all but
two MLST alleles in the Necker collection have been previ-
ously reported (Table 3), we conclude that most within-series
MLST variation arose prior to the onset of infection. However,
the limited number of samples available for any time point
compromises the accuracy with which we can estimate within-
series genetic variation. While our MLST data do not support
the inference that mutator series are more genetically variable
than nonmutators, it is noteworthy that the only novel alleles
found in this study were from patients with mutator strains (H
and I) (Table 3).
MLSA provides no evidence for between-strain recombina-
tion during chronic infection. Secondary infection provides
TABLE 2. Population genetic sequence diversity of
the Necker collection
Locus
Sequence
length
(nt)
No. of:
a Rmb FSTcSequences
sampled Alleles SNPs
acsA 810 49 12 21 0.0082 3 0.88
aroE 944 48 9 41 0.0136 5 0.97
guaA 832 49 11 13 0.0039 1 0.84
mutL 905 49 10 21 0.0073 4 0.90
nuoD 804 49 6 11 0.0037 0 0.97
ppsA 808 49 10 24 0.0076 3 0.78
trpE 575 48 9 20 0.0080 1 0.87
a , nucleotide diversity per nucleotide site.
b Rm, minimum number of recombination events.
c From AMOVA.
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opportunities for recombination between strains to create
novel genomic diversity of potential clinical importance. To
test for recombination, we used Rm (40), a conservative esti-
mator of the minimum number of recombination events in a
sample of nucleotide data that conform to the infinite-site
mutation model (i.e., where recurrent mutation has not oc-
curred and a maximum of two nucleotide identity states are
therefore observed at a position). For data that conform to this
model, the observation of all four possible genotypes between
a pair of polymorphic sites can be explained only by a recom-
bination event between the sites. With only a single exception
(in aroE), all SNPs in the MLSA data set conform to the
infinite-site model. Recombination was detected for six of the
seven loci (Table 2).
Recombination events are also evident in the genealogical
histories of the loci (Fig. 2). Genealogical networks accommo-
date recombination, as well as other scenarios that traditional
bifurcating phylogenies fail to accurately describe (66), such as
TABLE 3. Necker collection multilocus sequence typesa
Patient Strain
Alleleb
pubMLST typec
acsA aroE guaA mutL nuoD ppsA trpE
A A1 6 68 20 11 4 4 7 ST439
A2 6 68 20 11 4 4 7 ST439
B B1 1 5 5 7 4 6 7 ST1007
B2a 1 5 5 7 4 6 7 ST1007
B2b 125 5 6 3 4 13 7 ST1066
C C1 4 4 16 12 4 6 3 ST828
C2a 4 4 16 12 4 6 3 ST828
C2b 4 4 16 12 4 6 3 ST828
D D1 125 5 6 3 4 13 23 ST633
D2 125 5 6 3 4 13 23 ST633
E E1 23 5 11 7 1 12 7 ST274
E2 23 5 11 7 1 12 7 ST274
F F1 6 84 11 3 4 76 91 ST1008
F2 125 5 6 3 4 13 23 ST633
G G1 6 5 11 7 3 12 19 ST282
G2 6 5 11 7 3 12 19 ST282
H H1 39 4 1 11 4 12 2 ST1009
H2 39 4 1 11 4 12 136 ST1067
I I1 23 5 11 7 1 12 137 ST1068
I2 23 5 11 7 1 12 137 ST1068
I3a 23 5 11 7 1 12 137 ST1068
I3b 23 5 11 7 1 12 137 ST1068
I4 23 5 11 7 1 12 137 ST1068
J J1 28 5 36 3 3 13 7 ST155
J2a 28 5 36 3 3 13 7 ST155
J2b 28 5 36 3 3 1 7 ST1010
K K1 89 30 64 26 48 24 32 ST195
K2a 89 30 64 26 48 24 32 ST195
K2b 89 30 64 26 48 24 32 ST195
K3a 89 30 64 26 48 24 32 ST195
K3b 89 30 64 26 48 24 32 ST195
K4a 89 30 64 26 48 24 32 ST195
K4b 89 30 64 26 48 24 32 ST195
K5a 89 30 64 26 48 24 32 ST195
K5 89 30 64 26 48 24 32 ST195
L L1 40 84 11 3 4 76 91 ST675
L2 40 84 11 3 4 76 91 ST675
M M1 11 3 11 3 4 15 2 ST1011
M2 11 3 11 3 4 15 2 ST1011
M3a 11 3 11 3 4 15 2 ST1011
M3b 11 3 11 3 4 15 2 ST1011
N N1a 23 5 11 7 1 12 7 ST274
N1b 23 5 11 7 1 12 7 ST274
O O1 40 84 11 3 4 76 91 ST675
O2 7 5 12 3 4 1 7 ST549
P P1 40 68 20 11 29 4 7 ST1069
P2a 121 20 26 13 3 64 7 ST1012
P2b 121 20 26 13 3 64 7 ST1012
P2c 121 20 26 13 3 13 7 ST1013
a Shaded rows indicate instances of possible co-/cross-infection.
b MLST alleles were assigned based on the following nucleotide positions of the sequence data set: acsA, nt 95 to 484; aroE, nt 233 to 730; guaA, nt 273 to 645; mutL,
nt 453 to 894; nuoD, nt 86 to 451; ppsA, nt 1 to 370; trpE, nt 1 to 443. trpE136 and trpE137 (boldface) are novel alleles not previously reported in the global MLST
database.
c Boldface indicates novel pubMLST types reported here for the first time.
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ancestor-descendant relationships among extant alleles (with
ancestors at internal nodes in the network) and multifurca-
tions. Loci impacted by recombination are graphically repre-
sented as cycles (i.e., loops) in these networks to relate the four
genotypes arising from only two mutations (Fig. 2). Though the
respective evolutionary histories of these loci have been
shaped by recombination, these events predate the population
dynamics of the series under study, as the alleles connected via
recombination cycles have been previously reported (http:
//pubmlst.org/paeruginosa/) (Table 3). We therefore conclude
that recombination at these loci has not impacted the popula-
tion genetics of individual series during the period of chronic
infection for which we have records, including series for which
there is evidence of secondary infection.
Comparative analysis of a mutator series and a nonmutator
series. Patients I and M were roughly age matched (13.5 and
14.9 years old, respectively) as a surrogate for infection dura-
tion. Because neither series from these patients showed evi-
dence of P. aeruginosa co-/cross-infection by MLSA and be-
cause mutators were isolated from patient I but not from
patient M (Table 1), we chose to study genetic variation in
these two series comparatively and in greater detail. As a first
step toward discovering the mechanistic basis for the I-series
mutator phenotype and to test for the interesting possibility
that the later-arising I clones displayed lower mutation fre-
quencies due to compensatory mutations, we completely se-
quenced mismatch repair genes mutL and mutS, the loci most
frequently associated with the mutator phenotype (62).
Complete sequences for mutL and mutS reveal the basis for
mutator phenotypes in the I series. An alignment (see Fig. S4
in the supplemental material) of 2,568 bp of mutS from the I
and M series and four outgroups (Necker isolate K1, a Liver-
pool epidemic strain [LESB58], UCBPP-PA14, and PAO1)
revealed 59 polymorphic sites (see Table S3 in the supplemen-
tal material) with only one nonsynonymous change in K1M (nt
841; S 3 G) and a novel 8-bp deletion at nt 1194 to 1201
(Table 4). The latter results in a frameshift mutation and a
premature stop codon in I1, I2, I3a, and I3b. I3a and I3b
exhibit spontaneous mutation to Rifr frequencies that are an
order of magnitude lower than those of I1 and I2, falling just
below the cutoff to be classified as mutators (Table 1). Thus,
I3a and I3b may contain extragenic suppressors that partly
compensate for the loss of MutS activity.
The novel 8-bp deletion is not detected in I4, a bona fide
nonmutator (3.90E08) and the final isolate of the I series,
whose PFGE profiles and MLST haplotype match those of the
earlier strains. Together, these observations suggest that I-se-
ries hypermutators and nonmutators all originate from an I4-
like ancestor. The location of I4 at an internal node of a
minimum spanning network analysis supports this conclusion
(see see Fig. S3A in the supplemental material). Unlike diver-
sity indices such as , AMOVA calculations can consider the
presence or absence of nucleotides as a fifth state; therefore,
divergence due to deletion is reflected in the resulting distance
matrix and network diagram. The mutS network coincides with
FIG. 2. Genealogical relationships among alleles recovered from
the Necker collection for representative loci: ppsA (A), trpE (B), and
nuoD (C). The area of the node is proportional to the relative fre-
quency of the allele in the sample, and the wedge color corresponds to
the series color depicted in Fig. 1 and in Fig. S1 in ths supplemental
material. The sum of the branch lengths between two alleles corre-
sponds exactly to the number of nucleotide sequence differences ob-
served between them. Note the presence of cycles for loci impacted by
recombination. Black nodes represent alleles not observed in the
sample.
TABLE 4. Summary of mutS polymorphism
Isolate(s)
Base at nta:
336 342 357 594 804 951 996 1047 1120 1194–1201 1245 1506 1539 1575 1599 1650 1668 1902 1926 1998 2052 2181 2187
I1, I3a C C G G C G T T T Deletion G A A G C G C T G C T C G
I2 C C G G C G T T T Deletion G A A G T G C T G C T C G
I3b C C G G C G T T T Deletion G A A A C G C T G C T C G
I4 C C G G C G T T T CTATCCCG G A A G C G C T G C T C G
M1, M3a T T A A T A C C C CTATCCCG A G G G T A T C A C C T A
M2 T T A A T A C C C CTATCCCG A G G G C A T C A G C T A
M3b T T A A T A C C C CTATCCCG A G G G C A T C A C C T A
LESB58 C C G A T A C C C CTATCCCG A G G G C A T C A C C T A
PA14 C C G G C G T T T CTATCCCG G G G A T G C T G C T C G
PAO1 C C G A T A C C C CTATCCCG A G G G C A T C A C C T A
a Shaded changes are unique to a series and do not represent underlying polymorphism observed in reference strains.
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other data placing the I series in closer proximity to PA14 and
the M series nearer PAO1; K1 is a distant outlier, as in other
analyses.
Restricting comparisons to the mutator-containing I series
and the nonmutator M series, there are only 23 mutS polymor-
phisms (counting the 8-bp deletion in I-series mutators as a
single mutational event); 16 polymorphisms simply reflect the
underlying diversity of reference strains (Table 4; see Table S3
in the supplemental material). Seemingly contrary to a hypoth-
esis that hypermutator status should generate more molecular
diversity, four of the remaining polymorphisms are unique to
the M series, while only two are unique to the I series; how-
ever, caution should be exercised when drawing genome-wide
conclusions about diversity from just a few loci. The I series
does exhibit within-series diversity at two sites (nt 1575 and
1599), in addition to the 8-bp deletion. The M series also
exhibits polymorphism at nt 1599, suggesting that this site may
be prone to mutation.
In contrast to the case for the mutS locus, analysis of
1,902-bp mutL sequences (see Fig. S4B in the supplemental
material) indicates homogeneity in the I and M series (Table
5). Of 54 polymorphic sites (see Table S3 in the supplemental
material), K1 exhibited the only nonsynonymous change (nt 5;
S3 N) in this subset of Necker strains. Haplotypic differences
between the two patient series, outgroup isolate K1, and ref-
erence strains allowed construction of an alternate single-locus
minimum spanning network. The structure of the mutL mini-
mum spanning network reflects haplotypic similarity of the I
series to the Liverpool epidemic strain LESB58 (see Fig. S3B
in the supplemental material). M-series isolates appear to be
more closely related to lab strain PAO1, a result that is con-
sistent with MLST, a-CGH, and mutS network data.
Comparative genome hybridization shows that mutator and
nonmutator longitudinal series lack a common set of genes
found in P. aeruginosa PAO1. Analyses of genome fingerprints,
MLST haplotypes, and mutL and mutS sequences provided no
clear evidence that patient series from which we isolated mu-
tators were genetically more variable than series from which
we did not. Because mismatch repair (MMR)-deficient strains
are more prone to homologous recombination (63, 68, 18) and
thus susceptible to genome rearrangement, we also deter-
mined whether mutator and nonmutator populations exhibited
differences in genome content using Affymetrix PAO1 mi-
croarrays and validated the results using PFGRC arrays.
Microarray analyses indicated that 126 PAO1 open reading
frames (ORFs) could not be detected in multiple members of
the mutator and nonmutator series (Table 6); this represents
142.4 kb or 2.3% of the 6.3-Mbp PAO1 reference genome.
These genes fell into 49 contiguous blocks and consisted of 89
transcriptional units, 27 of which were polycistronic. A major-
ity (70/126) of these ORFs were in the PseudoCAP function
category “hypothetical, unclassified, unknown” (Table 6; see
Table S4A in the supplemental material). Of the remainder, 7
were related to “phage, transposon, or plasmid” and included
genes having homology to phage Pf1 (PA0717 and PA0724).
Fifty-eight fell into one or more of functional categories: “mo-
tility and attachment” (4), “cell wall/lipopolysaccharide (LPS)”
(15), “membrane proteins” (9), “transport of small molecules”
(9), and “putative enzymes” (21). Most of these 58 ORFs have
homology to proteins that carry out activities at the cell sur-
face, e.g., a block of 20 known virulence factors (PA3142 to
PA3160) dedicated to LPS O-antigen biosynthesis and export,
as well as pilin genes pilA and pilC and fimbrial chaperone
genes cupC1 and cupC2. Five PAO1 transcription factors were
also absent, two having the lysR family signature (PA0207 and
PA2220) and one, vqsM (PA2226), with 47% similarity to the
essential quorum-sensing regulator OruR. As a group, there-
fore, all nine strains isolated from these two patients share
attributes seen as characteristic of CRI in the cystic fibrosis
lung (20, 22, 80): loss of certain genes whose products, by
virtue of being secreted from or situated at the cell surface,
offer targets for the immune system and loss of others whose
products help mediate quorum sensing.
Comparative genome hybridization also illuminates differ-
ences in genome content between a mutator and a nonmutator
series. Of particular relevance to our study was the distribution
of PAO1 genes whose presence or absence distinguished the
nonmutator M series from the mutator I series. All strains in
the M series lacked 14 ORFs present in both PAO1 and every
member of the I series (Table 7; see Table S4B in the supple-
mental material). These genes were located in 8 contiguous
stretches of DNA and consisted of 14 transcriptional units, 4 of
which were polycistronic; most (12/14) were in the PseudoCAP
function class “hypothetical, unclassified, unknown.” A con-
spicuous genetic polymorphism was evident at the last sample
collection, as one of two strains isolated (M3b) had an addi-
tional 86-gene, 105-kb deletion (PA2425 to PA2510) as well
as a deletion in PA3904. The inference that this block of genes
was lost during chronic infection is supported by the facts that,
aside from this one large deletion, M-series isolates exhibit
identical MLST haplotypes (Table 3) and similar PFGE fin-
gerprints (Fig. 1B; see Fig. S1B in the supplemental material)
(but note the diminished size of second largest SpeI band in
M3b [Fig. 1B]). The large M3b deletion contains 53 transcrip-
tional units, of which 21 are polycistronic. Of 86 PAO1 genes
that are absent, almost half (40/86) are classified as “hypothet-
TABLE 5. Summary of mutL polymorphism
Isolate(s)
Base at nta:
103 321 396 498 531 558 726 750 1035 1308 1365 1470 1689 1704 1717 1743 1771 1815 1857 1858
I series C T T C A T T T G C C T C G T T C G A C
M series T C C T G C C C C T T G T G C C T A G T
LESB58 C T T T G C C C G C T T C G T T C A G T
PA14 C C C C A T C C C C C T C A T C C A G T
PAO1 C C C T G C C C C T T T T G C C T A G T
a Shaded changes are unique to a series and do not represent underlying polymorphism observed in reference strains.
4810 WARREN ET AL. INFECT. IMMUN.
TABLE 6. PAO1 genes not detected in either I or M series
Boundary Size (bp)
Presence in straina:
FunctionI series M series
I1 I2 I3a I3b I4 M1 M2 M3a M3b
PA0202-PA0207 6,568 Putative enzymes
Transport of small molecules
Membrane protein
Transcriptional regulator
PA0442 116 Unknown
PA0445 1,016 Related to phage, transposon, or plasmid
PA0642 788 Unknown
PA0715-PA0717 3,387 Related to phage, transposon, or plasmid
PA0724 1,262 Related to phage, transposon, or plasmid
PA0820 812 Unknown
PA0977 323 Unknown
PA0980-PA0981 943 Unknown
PA0983-PA0985 2,679 Membrane proteins, secreted factors
PA0992-PA0993 1,388 Motility and attachment
Motility and attachment
PA1133 350 Unknown
PA1152 344 Unknown
PA1204 557 Unknown
PA1239-PA1241 2,463 Putative enzymes
Transcriptional regulators
PA1368-PA1372 7,761 Unknown
PA1385 1,124 Cell wall/LPS/capsule
PA1394 254 Unknown
PA1509-PA1510 2,848 Unknown
Unknown
PA1887-PA1888 2,061 Unknown
PA1935-PA1936 1,067 Unknown
PA1939 1,997 Unknown
PA2037 1,460 Unknown
PA2046 407 Unknown
PA2218-PA2228 11,615 Membrane proteins
Transcriptional regulator
PA2372 572 Unknown
PA2427 467 Unknown
PA2456 341 Unknown
PA2459-PA2462 19,322 Unknown
PA2730-PA2736 10,319 Putative enzymes
PA2791 290 Unknown
PA2818-PA2819 2,125 Unknown
PA3142_i-PA3160_wzz 19,498 Cell wall/LPS/capsule, putative enzymes, amino
acid biosynthesis and metabolism, membrane
proteins, transport of small molecules
PA3292 857 Unknown
PA3298 302 Unknown
PA3486-PA3488 6,856 Fatty acid and phospholipid metabolism
PA3497-PA3514 16,113 Putative enzymes
Transcriptional regulator
Membrane proteins
Transport of small molecules
PA3577_i 113 Unknown
PA3866-PA3869 5,339 Adaptation, protection; secreted factors
DNA replication, recombination, modification,
and repair
PA4255_rpmC 191 Translation, posttranslational modification,
degradation
PA4306 218 Unknown
PA4485 377 Unknown
PA4503 1,010 Membrane proteins, transport of small molecules
PA4525_pilA 449 Motility and attachment
PA4527_pilC 1,124 Motility and attachment
PA4999 1,205 Unknown
PA5086-PA5087 1,747 Unknown
Unknown
Total size 142.4 kb
a Shading indicates that the gene is present in the genome.
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ical, unclassified, unknown,” while 23 fall into the functional
categories “adaptation and protection” (2), “membrane pro-
tein” (13), and “transport of small molecules” (8), activities
that likely occur at the cell surface. The deleted segment in-
cludes 3 known virulence factors (PA2425 to PA2427) involved
in pyoverdine gene expression. Also deleted are multiple ac-
tivities (sdaA, glyA2, gcvP2, and gcvH2) related to serine and
glycine metabolism as well as those encoded by the multidrug
efflux transporter genes mexE and mexF and their regulator,
mexT. Indeed, a remarkable aspect of this 105-kb deletion is
that 13 of the 86 PAO1 ORFs lost are known or putative
transcriptional regulators, including foxI, foxR, and the LysR
substrate gene bexR, in addition to mexT. While the ultimate
evolutionary fate of M3b is unknown, either the loss of these
genes, so many of which regulate gene expression, does not
impose a fitness cost or that cost is offset by fitness gains arising
from loss of virulence factors.
In contrast to 14 PAO1 ORFs that were absent from all
nonmutators (Table 7), microarray analysis uncovered 61
ORFs that were present in nonmutators but absent from the I
series (Table 8; see Table S4C in the supplemental material).
These genes fell into 20 contiguous blocks, and consisted of 33
transcriptional units, of which 16 are polycistronic. Remark-
ably, unlike the set of genes absent from both series or those
absent from the M series only, few (15/61) were classified as
“hypothetical, unclassified, or unknown.” Rather, a clear ma-
jority (35/61) fell into three PseudoCAP functional categories:
18 ORFs were “related to phage, transposon, or plasmids,”
including 14 clustered genes (PA0615 to PA0628) having ho-
mology to P. aeruginosa phage 
CTX and bacteriophage P2,
and another 17 ORFs were functionally related to “motility
and attachment” (9) and “adaptation and protection” (8). All
of the former are cotranscribed at operon 932 (PA4549 to
PA4556) and comprise genes encoding type IV fimbrial bio-
genesis proteins. Among the latter category are a contiguous
set of siderophore loci (PA2396 to PA2401) that constitute
virulence factors, as well as pyocin S2 killer protein and im-
munity genes (PA1150 to PA1151). I-series strains therefore
recapitulate the theme of loss of function in potential host
immune system targets seen in cystic fibrosis CRI. Further, of
15 ORFs having no known function, 6 have computationally
predicted export signals (see Table S4C in the supplemental
material). Overall, and even including the M3b deletion strain
in our analyses, the high-mutation-frequency I series is distin-
guished from the low-mutation-frequency M series by the ab-
sence of more PAO1 genes functionally related to mobile
elements, motility and attachment, and adaptation and protec-
tion, while retaining a nearly complete complement of PAO1
genes involved in carbon and central intermediary metabolism
and in antibiotic resistance (Fig. 3). Regarding this last obser-
vation, it is noteworthy that while no M-series strain was mul-
tiply antibiotic resistant, all but one of the I-series strains were
(Table 1).
DISCUSSION
P. aeruginosa population genetic structure in nature and in
the clinic. P. aeruginosa is a ubiquitous microbe that can be
isolated from soils, waters, and plant surfaces, as well as from
infection sites of immunocompromised individuals (53). Al-
though environmental P. aeruginosa strains differ widely in
genome content (47, 51), evidence suggests that most retain
infectious potential (93). The conserved P. aeruginosa core
genome contains recombinogenic regions where genomic con-
TABLE 7. PAO1 genes not detected in M series only
Boundary Size (bp)
Presence in straina:
Function
M1 M2 M3a M3b
PA0053 254 Unknown
PA0643 1,091 Unknown
PA0982 548 Unknown
PA1366 770 Unknown
PA2073-PA2074 2,242 Transport of small molecules
Unknown
PA2425-PA2510_catR 107,346 Putative enzymes
Transcriptional regulator
Membrane proteins
Transport of small molecules
Amino acid biosynthesis and metabolism
Central intermediary metabolism
Carbon compound catabolism
Adaptation, protection
Chaperones and heat shock proteins
Translation, posttranslational modification, degradation
Two-component regulatory systems
Energy metabolism
Antibiotic resistance and susceptibility
Carbon compound catabolism
PA2794 1,316 Unknown
PA3291 554 Unknown
PA3904_i 395 Unknown
Total 114.5 kb
a Shading indicates that the gene is present in the genome.
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tent is modulated by entry and exit of plasmids (46), integrons
(23), and other active mobile genetic elements (69). Incorpo-
ration of certain accessory elements into the core genome may
in some cases exclude others, resulting in different regulatory
networks and antibiotic resistance profiles (51, 93). For exam-
ple, Kiewitz et al. reported two reversible entry sites for a
106-kbp plasmid among sequential P. aeruginosa isolates (46).
Strains occupying the same habitat may therefore possess iden-
tical accessory elements but regulate them differently accord-
ing to where they are integrated.
Because the P. aeruginosa genome is malleable, the total
population genetic diversity observed locally can approach that
observed globally (92). Still, regionally dominant clones can
arise and become disproportionately represented in a particu-
lar hospital or in closely associated groups of patients and
family members (3, 41, 86). Although it is widely accepted that
CF patients generally acquire infections from environmental
reservoirs (71), cross-infection has been reported between pa-
tients harboring strains especially adept at colonization (44).
Typically, however, such instances of cross-infection occur be-
tween CF patients having prolonged contact, such as siblings,
or between uninfected and infected CF patients at clinics
where patients are not segregated. Also, a recent study re-
ported an apparent link between host CFTR genotype ho-
mozygous F508del and susceptibility to transmissible strains
(45). Transmissible-strain infections are generally associated
with worse clinical outcomes (1).
Clonality and secondary infection in the Necker collection.
The population genetic structure of the Necker isolates con-
forms to the view that local diversity can approach that seen
globally (92). Genome fingerprint and MLST data indicate
that the first strain isolated from each longitudinal series is
genetically distinct from the first strain isolated from other
series. Necker strains cluster within individual patients as
clonal groups, with no evidence for interclonal recombination
over periods of up to 25 months. Significantly, every patient in
our study group entered the Necker CF clinic for treatment
and sampling during 2002 (Table 1; see Fig. S5 in the supple-
mental material). In most cases genome fingerprint and MLST
data provide no evidence for co-/cross-infection among pa-
TABLE 8. PAO1 genes not detected in I series only
Boundary Size (bp)
Presence in straina:
Function
I1 I2 I3a I3b I4
PA0098-PA0099 2,197 Unknown
PA0100 920 Unknown
PA0497-PA0499 2,803 Unknown
Motility and attachment, chaperones and heat shock proteins
PA0615-PA6028 12,085 Related to phage, transposon, or plasmid
PA0646-PA0648 1,581 Unknown
PA0719 377 Related to phage, transposon, or plasmid
PA0723_coaB 248 Related to phage, transposon, or plasmid
PA0729 347 Unknown
PA0821-PA0824 2,321 Unknown
PA1150_pys2-PA1151_imm2 2,334 Adaptation, protection
Secreted factors (toxins, enzymes, alginate)
PA1664 140 Unknown
PA1914 1,226 Unknown
PA2036 521 Unknown
PA2100-PA2106 6,801 Transcriptional regulator
Biosynthesis of cofactors, prosthetic groups, and carriers
Amino acid biosynthesis and metabolism
Putative enzymes
PA2386_pvdA-PA2387 1,943 Adaptation, protection
Transcriptional regulator
PA2392 1,634 Unknown
PA2396-PA2401 19,398 Unknown
Adaptation, protection
Transport of small molecules
Secreted factors (toxins, enzymes, alginate)
Membrane proteins
PA2403 1,211 Unknown
PA2816 380 Unknown
PA4514 2,261 Transport of small molecules
PA4549_fimT-PA4556_pilE 7,342 Motility and attachment
PA5191 356 Unknown
Total 68.4 kb
a Shading indicates that the gene is present in the genome.
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tients. However, three clones isolated from patients D (D1 and
D2) and F (F2) exhibit identical 7-locus MLST genotypes, and
three clones isolated from patients L (L1 and L2) and O (O1)
share a different 7-locus MLST genotype. In both groups,
among-strain MLST identity is reflected in similar PFGE fin-
gerprints (Fig. 1B; see Fig. S1B in the supplemental material).
Further, strains isolated from patients D and F have identical
CLONDIAG SNP-chip profiles that differ from identical SNP-
chip profiles shared by strains from patients L and O (N.
Cramer and B. Tümmler, unpublished data). Although posti-
solation cross-contamination is formally possible, these obser-
vations, coupled with the facts that patients overlapped in their
treatment schedules and were homozygous for the F508del
CFTR mutation, more likely indicate secondary infection.
Establishment of chronic P. aeruginosa infections in the CF
lung: successful colonists may not make successful residents.
Evidence now suggests that following multiple acute episodes
early in life, CF patients are colonized by one or a few persis-
tent P. aeruginosa strains that establish a chronic infection (44,
61). Transition from the acute to chronic phase is often marked
by the appearance of mucA mutants that produce copious
exopolysaccharide (EPS) (19), as well as by differential regu-
lation of the GAC histidine sensor-kinase complex (26). We
observed both mucoid and nonmucoid phenotypes within lin-
eages, sometimes isolated from the same patient at the same
time (Table 1, patients B, J, and K). This observation may
reflect heterogeneity in the lung environment and/or clonal
differentiation as strains adaptively radiate to anaerobic niches
within the lung (94) or to aerobic regions in the upper respi-
ratory tract (39, 44). We also observe instances where a mucoid
strain fingerprint is later observed in a nonmucoid strain (Fig.
1; see Fig. S1 in the supplemental material [patient K]). These
findings, considered in light of the fact that mucoid reversion
to the nonmucoid phenotype can occur by a single point mu-
tation in algT (19), raise the possibility that mucoid polymor-
phism may be an example of “social cheating” (74). Overpro-
duction of EPS promotes bacterial colony formation and
attachment to epithelial surfaces, and biofilms consolidated
with EPS appear to be more resistant to antibodies and anti-
biotics (31, 55). However, because EPS overproduction carries
a cost and because reversion can occur at high frequency,
nonmucoid strains may arise that enjoy the benefits of a “pub-
lic good,” namely, EPS, without having to bear the burden of
its synthesis.
P. aeruginosa strains residing in the CF lung are polymor-
phic but experience limited gene flow with P. aeruginosa
strains living in the external environment. Traits required for
P. aeruginosa to successfully invade and colonize the CF lung
appear to differ from those required for it to persist (76).
Motility, type III secretion, and O-antigen biosynthesis, impor-
tant factors in the onset of an acute infection, are commonly
lost during the course of chronic infection (28, 43, 52). Over
time, progressive loss of these traits should diminish the like-
lihood of transmission between CF hosts. Moreover, because
the number of cells in an established population is vastly
greater than the number of any new colonist cells, established
FIG. 3. Percentages of PAO1 genes detected in the I and M series by functional category.
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P. aeruginosa populations should resist invasion by novel envi-
ronmental strains. Thus, while horizontal gene transfer can
shape genome architecture in the external environment (67),
most evidence suggests that evolutionary dynamics of chronic
P. aeruginosa infections in the CF lung are driven by vertical
gene transfer (77, 83). Successive clones within patients should
therefore more closely resemble one another than those in
other patients.
Analysis of the Necker collection generally upholds this pre-
diction: genome fingerprints (Fig. 1; see Fig. S1 in the supple-
mental material) and MLST haplotypes (Table 3) cluster
within series. Nevertheless, Necker isolates exhibit extensive
phenotypic variation, evident as polymorphism in antibiotic
sensitivities, mucoidy, and spontaneous mutation to rifampin
resistance within all 16 patient series. MLST analysis reveals
genetic polymorphism in 6 of 16 series. Of these six, two (F and
O) appear to be polymorphic by virtue of secondary infection
involving strains shared with patients D and L, respectively.
Significantly, the MLSA-based inference of clonal relatedness
of both D isolates to F2 and relatedness of both L isolates to
O1 is supported by PFGE data (Fig. 1B; see Fig. S1B in the
supplemental material). Of the other patient series that 7-locus
MLSA reveals to be polymorphic, four (H, I, J, and P) contain
mutators, and clonal relatedness is discernible in three: J is
polymorphic only at pps, and H and I are polymorphic only at
trpE. Overall, MLST polymorphism is greatest in the all-mu-
tator P series.
Population genetic structure in the Necker collection thus
appears to arise from each patient being successfully colonized
by an environmental strain, possibly including those originating
from other patients, followed by chronic infections wherein
relatedness is evident among successively isolated clones. Su-
perimposed on this underlying structure is widespread pheno-
typic and genotypic polymorphism, in several instances arising
from likely co-/cross-infection and in others presumably from
the interaction of selection, drift, and mutation, the last of
which is augmented in MMR-deficient mutators.
Considering the limited number of strains isolated from
each patient and the limited amount of sequence data obtained
for any strain, the amount of phenotypic and genetic diversity
that we report almost certainly underestimates total P. aerugi-
nosa diversity within and among patients (24). Unfortunately,
sampling limitations complicate inference of ancestor-descen-
dant relationships, making it difficult to distinguish alternative
evolutionary models of clonal succession and clonal interfer-
ence. Distinguishing between these alternatives will require a
much more extensive assessment of within-patient clonal di-
versity, involving scores rather than pairs of strains isolated at
regular time intervals, regardless of whether or not the patient
is suffering from acute exacerbation of symptoms.
Parallel evolution in P. aeruginosa strains chronically infect-
ing the CF lung. In addition to selective pressures arising from
interactions with other microbes (48, 77), P. aeruginosa evolves
in the CF lung under host-specific pressures that include im-
mune system surveillance, intermittent antibiotic therapy, low
iron availability, and physicochemical factors arising from de-
fects in the CFTR gene, notably copious secretions abundant
in branched-chain amino acids and low O2 tension (29, 94).
Because these same selective pressures occur to various de-
grees in all CF patients, it is perhaps not surprising to find
parallel adaptive evolution in P. aeruginosa, specifically loss-
of-function mutations in motility, type III secretion, O-antigen
biosynthesis, and production of virulence factors such as exo-
toxins, phenazine, and proteases (78), as well as diminished
expression of type IV fimbrial biogenesis genes (42). Indeed,
many of the functions required to invade and successfully col-
onize the CF lung are dispensed with as P. aeruginosa transi-
tions from acute to chronic infection, presumably because the
secreted molecules associated with these functions provide in-
viting targets for the host immune system (60). Other parallel
changes include regulatory mutations in mucA that may en-
hance cells’ propensity to form biofilms, mutations in mexZ
that increase expression of multidrug efflux pumps (2, 78), and
loss-of-function mutations in lasR, a central regulator of inter-
cellular quorum sensing via the synthesis and recognition of
acyl-homoserine lactones. Relative to wild-type strains, lasR
mutants exhibit multiple phenotypes that are likely to increase
fitness in the CF lung; these include improved growth on
amino acids that are abundant in CF lung secretions (7) and
metabolic shifts that diminish O2 consumption and increase
nitrate utilization (37), which indirectly enhance tobramycin
and ciprofloxacin resistance (37).
Comparative genome hybridization suggests parallel evolu-
tion in longitudinal series that contain or lack mutators. Mi-
croarray analysis shows that P. aeruginosa strains in two patient
series lack 70 genes categorized as “hypothetical, unclassi-
fied, unknown.” However, both series also lack nearly as many
genes that fall into categories where loss of function has been
associated with CRI. Most of the latter have homology to cell
surface protein genes and include virulence determinants as-
sociated with LPS O-antigen biosynthesis and export, as well as
pilins and fimbrial chaperones. Multiple transcription factors
were also absent, two having the lysR family signature and one
(vqsM) having similarity to the quorum-sensing regulator
OruR. Of the PAO1 genes whose absence distinguishes the
nonmutator M series from the mutator I series, most (12/14)
have no known function. In contrast, many (18/61) of the
PAO1 loci whose absence distinguishes the mutator-containing
I series are related to phages, transposons, or plasmids, includ-
ing a cluster of 14 genes homologous to P. aeruginosa phage

CTX and bacteriophage P2. Another 17 ORFs were func-
tionally related to motility and attachment and to adaptation
and protection. Many of the former are cotranscribed and
encode type IV fimbrial biogenesis proteins, whereas several of
the latter encode siderophore proteins, which are recognized
virulence factor loci where diversity has previously been ob-
served (79).
The 105-kb deletion that we uncovered in nonmutator M3b
also fits the pattern of parallel phenotypic evolution during
chronic infection. This single massive deletion results in loss of
function in activities related to serine and glycine metabolism,
regulation of mex multidrug efflux transporters, and multiple
virulence factors related to pyoverdine gene expression. Dele-
tions of similar size involving pyoverdine loci have been ob-
served in strains from other collections (20), indicating that
such deletants may have an adaptive advantage in the CF lung
environment.
Evolution of mutators: another example of parallel evolu-
tion. In additional to loss-of-function and regulatory muta-
tions, P. aeruginosa isolates from chronic but not from acute
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CF infections show a high incidence of defects in DNA repair
and error avoidance pathways (63), resulting in heritable mu-
tators that should increase population genetic variation. First
reported by Oliver et al. (61), the unusually high incidence of
P. aeruginosa mutators in CF patients has since been associated
with hallmark features of chronic infection: antibiotic resis-
tance (this study and references 21, 38, and 63), cytotoxicity to
bronchial epithelial cells (38), increased anaerobic and mi-
croaerobic respiration (35), and attenuation of virulence (38,
58). Ferroni et al. (21) recently reported diminished host lung
function as a function of increased incidence of MMR-defi-
cient strains, though they concede that this observation could
be an artifact of increased mutator incidence in late-stage
infections.
Examining genome sequences from the endpoints of an
8-year infection, Smith et al. (78) confirmed that many of the
characteristic phenotypes of chronic CF isolates could be at-
tributed to mutations in mexZ, mexA, lasR, and vfr and further
that there was a strong bias toward nonsynonymous changes, as
would be expected if those mutations were under positive
selection. Using the complete set of genes in which mutations
were seen to occur, those authors screened intervening strains
in the 8-year patient series, as well as series in 29 other pa-
tients, and found additional evidence to support the inferences
of parallel evolution and positive selection.
Do mutators catalyze evolutionary change? (i) Conflicting
evidence from recent studies. The late-stage (96-month) iso-
late for which Smith et al. (78) collected whole-genome se-
quence data was a mutator, bearing a single nonsynonymous
change in mutS. Mena et al. (58) screened the entire collection
and found that while only 17% of strains exhibited a mutator
phenotype, a disproportionate number of all mutations in the
collection were carried in mutator genomes (e.g., 87% of
clones had 7 mutations). Indeed, sequential mutator lineages
accumulated 3 mutations per year, while nonmutators accu-
mulated 0.25 mutation per year. Strikingly, Mena et al. uncov-
ered an instance where two independent MMR-inactivating
mutations occurred in the same lineage (lesions in mutL and
mutS), providing even stronger evidence for positive selection
for the mutator trait.
While mutators show the capacity to accelerate mutation
accumulation in the CF lung, they are not a necessary prereq-
uisite to characteristic adaptive changes such as the switch to
mucoidy and the loss of quorum sensing. Examining 70 strains
isolated as longitudinal series from 10 patients, Ciofu et al. (11)
reported that mucA and lasR mutations usually preceded mu-
tations in antimutator genes. They also saw pervasive polymor-
phism in their collection, manifest as long-term coexistence of
clones that were strong, weak, and nonmutators, with hyper-
mutators being amplified in later stages by hitchhiking along
with strongly selected antibiotic-resistant variants (11). Thus,
overall, the picture of P. aeruginosa evolutionary dynamics
emerging from these studies is one of periodic selection on an
ancestral clone manifest as intermittent clonal expansion, with
multiple, related genotypes coexisting over extended periods of
time. Mutators appear to have accelerated rates of mutation
accumulation, hitchhiking along with late-stage adaptive mu-
tations, especially those that confer drug resistance.
(ii) Evidence from the Necker collection. If most P. aerugi-
nosa genes are vertically transmitted in the CF lung, then
evolution of genetic novelty in this environment depends on
the rate of mutation supply. Theory suggests that relative to
small populations in constant environments, large populations
that undergo strong and/or variable selection are supplied with
many more beneficial mutations (8). However, under these
circumstances, the number of favorable adaptations that attain
high frequency may be limited by competition among clones
with different but equally beneficial mutations (33, 17). Should
clonal interference delay successive sweeps of the fittest geno-
types, population genetic variation should increase over time.
However, because we have imperfect knowledge of P. aerugi-
nosa deme size and population genetic structure in the CF
lung, it is unclear how often conditions favor clonal interfer-
ence.
Genetic novelty may also originate from mutators, which are
a conspicuous feature of P. aeruginosa evolving in the CF lung
(61, 64). Theory and anecdotal evidence suggest that within the
CF lung strong and variable selective pressures intermittently
favor mutators, enabling mutator alleles to hitchhike along
with the adaptive mutations they help generate (83). Although
previous studies (16, 54, 59) as well as our own have shown
positive correlation between mutator status and multiple anti-
biotic resistance, it is not yet certain how much mutators con-
tribute to adaptive genetic variation. Because the evolutionary
disadvantages associated with an elevated mutation rate limit
the long-term evolutionary success of a mutator lineage (25),
favorable traits generated by mutators should persist only
within descendant nonmutator lineages. In our collection, the
I patient series shows genomic architectures in early mutator
isolates that appear later in nonmutators. These observations
may reflect the persistence of a selectively favored architecture
established by or passaged through a mutator lineage. Under
the latter scenario, an adaptive architecture arose within a
nonmutator lineage in which the I1 mutS allele appeared and
transiently hitchhiked. Nonmutator I4, the last isolate in this
series, does not contain the 8-bp mutS I1 deletion and exhibits
a background frequency of mutation to rifampin resistance. I3a
and I3b do contain the 8-bp mutS deletion and exhibit muta-
tion frequencies that are below the mutator cutoff but still
severalfold higher than the population median (Table 1). This
suggests that in I3a and I3b compensatory mutations rather
than reversions may have diminished the cost of an elevated
mutation rate, enabling these genotypes to retain adaptive
changes generated via hypermutation. How often and by what
mechanism(s) this occurs remain to be discovered.
Concluding remarks. The goals of this study were to assay
phenotypic and genotypic variability among P. aeruginosa
strains evolving in CF patients and to assess the relative con-
tributions of secondary infection, recombination, and mutator
activity to that variability. Our results support the view that
chronic infections are established independently by one or a
few founder clones from environmental reservoirs (10) and
that their evolutionary trajectories are rarely influenced by
recombination and horizontal gene transfer, even though co-/
cross-infection is not uncommon. The mutator incidence in the
Necker collection was comparable to those in previous reports
(reference 61 and others), and while mutators were more likely
to be antibiotic resistant, their presence in longitudinal series
was not associated with significant differences in genetic vari-
ability assessed by genome fingerprinting and MLST profiling.
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In two age-matched series with or without mutators, microar-
ray assay revealed a widespread absence of genes whose loss of
function has been associated with P. aeruginosa adaptation
during chronic infection, with the mutator series further dis-
tinguished by the absence of more such genes than the non-
mutator series. However, mutator status was not required to
generate adaptive macromutations, as a large deletion discov-
ered in the nonmutator series resulted in loss of multiple vir-
ulence factors. Much more intensive sampling of longitudinal
isolates is needed to gain deeper insights into the population
diversity and evolutionary dynamics of P. aeruginosa in the CF
lung, as well as the special role, if any, that mutators may play
in disease progression.
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71. Römling, U., J. Wingender, H. Müller, and B. Tümmler. 1994. A major
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